英国COVID-19住院患者细菌与真菌合并感染回顾性队列研究
该回顾性研究分析了伦敦两家医院836例确诊SARS-CoV-2住院患者,早期细菌合并感染率为3.2%,全程为6.1%,未发现伴随真菌感染,且与流感对照组相比合并感染率相近。
要点
- COVID-19住院早期细菌合并感染率低(3.2%)。
- 未检测到伴随真菌感染,侵袭性真菌感染仅3例且与导管相关。
- 与流感对照组相比,合并感染率无显著差异。
核心结论
- COVID-19住院患者早期细菌合并感染频率低,且未发现伴随真菌感染。
研究设计与样本
- 回顾性观察性研究,纳入2020年2月20日至4月20日伦敦两家NHS医院836例PCR确诊SARS-CoV-2住院患者,并与2019-2020流感季流感阳性住院患者对照。
主要发现
- 836例中27例(3.2%)在入院0-5天内分离出早期细菌,全程51例(6.1%)。
- 血培养阳性60例(7.1%),其中39例为污染菌;确诊呼吸感染相关菌血症2例。
- 导管相关菌血症6例(念珠菌3例、肠球菌2例、铜绿假单胞菌1例)。
- 未检出肺炎链球菌、军团菌或流感合并感染;社区获得性合并感染中金黄色葡萄球菌最常见(4/24,16.7%)。
- 侵袭性真菌感染3例,均归因于导管相关感染。
关键数值与推荐
- 早期细菌合并感染率3.2%(27/836),全程6.1%(51/836)。
- 血培养阳性率7.1%(60/836),污染率39/60。
- 流感对照组临床相关菌血症2/141(1.4%),呼吸道培养阳性10/38(26.3%),肺炎链球菌抗原阳性1/19(5.3%)。
临床怎么用
- COVID-19住院早期细菌合并感染率低,应避免常规经验性广谱抗菌药物。
- 需警惕导管相关血流感染,尤其是真菌感染。
局限性
- 回顾性观察性设计,单地域两中心,外推性受限。
- 微生物送检率不统一,可能低估合并感染。
- 未报告全部患者的详细临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the incidence of bacterial and fungal coinfection of hospitalized patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in this retrospective observational study across two London hospitals during the first UK wave of coronavirus disease 2019 (COVID-19). METHODS: A retrospective case series of hospitalized patients with confirmed SARS-CoV-2 by PCR was analysed across two acute NHS hospitals (20 February-20 April 2020; each isolate reviewed independently in parallel). This was contrasted to a control group of influenza-positive patients admitted during the 2019-2020 flu season. Patient demographics, microbiology and clinical outcomes were analysed. RESULTS: A total of 836 patients with confirmed SARS-CoV-2 were included; 27 (3.2%) of 836 had early confirmed bacterial isolates identified (0-5 days after admission), rising to 51 (6.1%) of 836 throughout admission. Blood cultures, respiratory samples, pneumococcal or Legionella urinary antigens and respiratory viral PCR panels were obtained from 643 (77%), 110 (13%), 249 (30%), 246 (29%) and 250 (30%) COVID-19 patients, respectively. A positive blood culture was identified in 60 patients (7.1%), of which 39 were classified as contaminants. Bacteraemia resulting from respiratory infection was confirmed in two cases (one each community-acquired Klebsiella pneumoniae and ventilator-associated Enterobacter cloacae). Line-related bacteraemia was identified in six patients (three Candida, two Enterococcus spp. and one Pseudomonas aeruginosa). All other community-acquired bacteraemias (n = 16) were attributed to nonrespiratory infection. Zero concomitant pneumococcal, Legionella or influenza infection was detected. A low yield of positive respiratory cultures was identified; Staphylococcus aureus was the most common respiratory pathogen isolated in community-acquired coinfection (4/24; 16.7%), with pseudomonas and yeast identified in late-onset infection. Invasive fungal infections (n = 3) were attributed to line-related infections. Comparable rates of positive coinfection were identified in the control group of confirmed influenza infection; clinically relevant bacteraemias (2/141; 1.4%), respiratory cultures (10/38; 26.3%) and pneumococcal-positive antigens (1/19; 5.3%) were low. CONCLUSIONS: We found a low frequency of bacterial coinfection in early COVID-19 hospital presentation, and no evidence of concomitant fungal infection, at least in the early phase of COVID-19.
引用
- Hughes S, Troise O, Donaldson H, et al. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020. PMID: 32603803. doi:10.1016/j.cmi.2020.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。